Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res

Retrieve available abstracts of 143 articles:
HTML format
Text format



Single Articles


    September 2017
  1. LEGARE S, Chabot C, Basik M
    SPEN, a new player in primary cilia formation and cell migration in breast cancer.
    Breast Cancer Res. 2017;19:104.
    PubMed     Text format     Abstract available


  2. ALI MA, Czene K, Eriksson L, Hall P, et al
    Breast Tissue Organisation and its Association with Breast Cancer Risk.
    Breast Cancer Res. 2017;19:103.
    PubMed     Text format     Abstract available


  3. MORI H, Chen JQ, Cardiff RD, Penzvalto Z, et al
    Pathobiology of the 129:Stat1 -/- mouse model of human age-related ER-positive breast cancer with an immune infiltrate-excluded phenotype.
    Breast Cancer Res. 2017;19:102.
    PubMed     Text format     Abstract available


    August 2017
  4. YUAN Y, Vora N, Sun CL, Li D, et al
    Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.
    Breast Cancer Res. 2017;19:101.
    PubMed     Text format     Abstract available


  5. CURTIT E, Pivot X, Henriques J, Paget-Bailly S, et al
    Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
    Breast Cancer Res. 2017;19:98.
    PubMed     Text format     Abstract available


  6. KERLIKOWSKE K, Ma L, Scott CG, Mahmoudzadeh AP, et al
    Combining quantitative and qualitative breast density measures to assess breast cancer risk.
    Breast Cancer Res. 2017;19:97.
    PubMed     Text format     Abstract available


  7. STURGEON SR, Pilsner JR, Arcaro KF, Ikuma K, et al
    White blood cell DNA methylation and risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Breast Cancer Res. 2017;19:94.
    PubMed     Text format     Abstract available


  8. ARANGO NP, Yuca E, Zhao M, Evans KW, et al
    Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
    Breast Cancer Res. 2017;19:93.
    PubMed     Text format     Abstract available


  9. BROWNE AJ, Kubasch ML, Gobel A, Hadji P, et al
    Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.
    Breast Cancer Res. 2017;19:92.
    PubMed     Text format     Abstract available


  10. PELEKANOU V, Carvajal-Hausdorf DE, Altan M, Wasserman B, et al
    Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Breast Cancer Res. 2017;19:91.
    PubMed     Text format     Abstract available


  11. MARTIN JL, Julovi SM, Lin MZ, de Silva HC, et al
    Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Breast Cancer Res. 2017;19:90.
    PubMed     Text format     Abstract available


  12. JHAVERI K, Wang R, Teplinsky E, Chandarlapaty S, et al
    A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Breast Cancer Res. 2017;19:89.
    PubMed     Text format     Abstract available


  13. KABRAJI S, Sole X, Huang Y, Bango C, et al
    AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.
    Breast Cancer Res. 2017;19:88.
    PubMed     Text format     Abstract available


    July 2017
  14. TOOMEY S, Eustace AJ, Fay J, Sheehan KM, et al
    Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Breast Cancer Res. 2017;19:87.
    PubMed     Text format     Abstract available


  15. HUGO HJ, Gunasinghe NPAD, Hollier BG, Tanaka T, et al
    Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Breast Cancer Res. 2017;19:86.
    PubMed     Text format     Abstract available


  16. SHAWON MSR, Eriksson M, Li J
    Body size in early life and risk of breast cancer.
    Breast Cancer Res. 2017;19:84.
    PubMed     Text format     Abstract available


  17. REINER AS, Lynch CF, Sisti JS, John EM, et al
    Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Breast Cancer Res. 2017;19:83.
    PubMed     Text format     Abstract available


  18. FORTNER RT, Tolockiene E, Schock H, Oda H, et al
    Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case-control study in the Northern Sweden Maternity Cohort.
    Breast Cancer Res. 2017;19:82.
    PubMed     Text format     Abstract available


  19. BROUWERS B, Fumagalli D, Brohee S, Hatse S, et al
    The footprint of the ageing stroma in older patients with breast cancer.
    Breast Cancer Res. 2017;19:78.
    PubMed     Text format     Abstract available


  20. SHENOUDA MM, Gillgrass A, Nham T, Hogg R, et al
    Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
    Breast Cancer Res. 2017;19:76.
    PubMed     Text format     Abstract available


    June 2017
  21. MORRISON JOLY M, Williams MM, Hicks DJ, Jones B, et al
    Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Breast Cancer Res. 2017;19:74.
    PubMed     Text format     Abstract available


  22. POLESZCZUK J, Luddy K, Chen L, Lee JK, et al
    Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.
    Breast Cancer Res. 2017;19:75.
    PubMed     Text format     Abstract available


  23. ZHANG G, Zhang W, Li B, Stringer-Reasor E, et al
    MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer.
    Breast Cancer Res. 2017;19:73.
    PubMed     Text format     Abstract available


  24. PRABHAKARAN S, Rizk VT, Ma Z, Cheng CH, et al
    Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes.
    Breast Cancer Res. 2017;19:71.
    PubMed     Text format     Abstract available


  25. WANG J, Song C, Tang H, Zhang C, et al
    miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Breast Cancer Res. 2017;19:72.
    PubMed     Text format     Abstract available


  26. SAKURAI M, Miki Y, Takagi K, Suzuki T, et al
    Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.
    Breast Cancer Res. 2017;19:70.
    PubMed     Text format     Abstract available


  27. TERRY MB, Keegan THM, Houghton LC, Goldberg M, et al
    Pubertal development in girls by breast cancer family history: the LEGACY girls cohort.
    Breast Cancer Res. 2017;19:69.
    PubMed     Text format     Abstract available


  28. SEACHRIST DD, Sizemore ST, Johnson E, Abdul-Karim FW, et al
    Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.
    Breast Cancer Res. 2017;19:66.
    PubMed     Text format     Abstract available


  29. SMITH SE, Mellor P, Ward AK, Kendall S, et al
    Molecular characterization of breast cancer cell lines through multiple omic approaches.
    Breast Cancer Res. 2017;19:65.
    PubMed     Text format     Abstract available


    May 2017
  30. MELLONI GEM, Mazzarella L, Bernard L, Bodini M, et al
    A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.
    Breast Cancer Res. 2017;19:63.
    PubMed     Text format     Abstract available


  31. GUO C, Sung H, Zheng S, Guida J, et al
    Age-related terminal duct lobular unit involution in benign tissues from Chinese breast cancer patients with luminal and triple-negative tumors.
    Breast Cancer Res. 2017;19:61.
    PubMed     Text format     Abstract available


  32. ST JOHN ER, Balog J, McKenzie JS, Rossi M, et al
    Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery.
    Breast Cancer Res. 2017;19:59.
    PubMed     Text format     Abstract available


  33. BAHREINI A, Li Z, Wang P, Levine KM, et al
    Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Breast Cancer Res. 2017;19:60.
    PubMed     Text format     Abstract available


  34. CANDIDO DOS REIS FJ, Wishart GC, Dicks EM, Greenberg D, et al
    An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.
    Breast Cancer Res. 2017;19:58.
    PubMed     Text format     Abstract available


  35. VARGA Z, Lebeau A, Bu H, Hartmann A, et al
    An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper(R).
    Breast Cancer Res. 2017;19:55.
    PubMed     Text format     Abstract available


  36. CHIA SK, Ellard SL, Mates M, Welch S, et al
    A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
    Breast Cancer Res. 2017;19:54.
    PubMed     Text format     Abstract available


  37. CHI L, Zou Y, Qin L, Ma W, et al
    TIMELESS contributes to the progression of breast cancer through activation of MYC.
    Breast Cancer Res. 2017;19:53.
    PubMed     Text format     Abstract available


  38. CLARKE CA, Canchola AJ, Moy LM, Neuhausen SL, et al
    Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.
    Breast Cancer Res. 2017;19:52.
    PubMed     Text format     Abstract available


    April 2017
  39. CHOY C, Ansari KI, Neman J, Hsu S, et al
    Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.
    Breast Cancer Res. 2017;19:51.
    PubMed     Text format     Abstract available


  40. CARTER EP, Gopsill JA, Gomm JJ, Jones JL, et al
    A 3D in vitro model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer.
    Breast Cancer Res. 2017;19:50.
    PubMed     Text format     Abstract available


  41. PAQUET ER, Lesurf R, Tofigh A, Dumeaux V, et al
    Erratum to: Detecting gene signature activation in breast cancer in an absolute, single-patient manner.
    Breast Cancer Res. 2017;19:48.
    PubMed     Text format    


  42. CORDONE I, Masi S, Summa V, Carosi M, et al
    Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study.
    Breast Cancer Res. 2017;19:46.
    PubMed     Text format     Abstract available


  43. TOI M, Shao Z, Hurvitz S, Tseng LM, et al
    Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
    Breast Cancer Res. 2017;19:47.
    PubMed     Text format     Abstract available


  44. YAGHJYAN L, Arao R, Brokamp C, O'Meara ES, et al
    Association between air pollution and mammographic breast density in the Breast Cancer Surveilance Consortium.
    Breast Cancer Res. 2017;19:36.
    PubMed     Text format     Abstract available


    March 2017
  45. AURE MR, Vitelli V, Jernstrom S, Kumar S, et al
    Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
    Breast Cancer Res. 2017;19:44.
    PubMed     Text format     Abstract available


  46. LEE YF, Miller LD, Chan XB, Black MA, et al
    Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
    Breast Cancer Res. 2017;19:42.
    PubMed     Text format    


  47. DAI M, Al-Odaini AA, Arakelian A, Rabbani SA, et al
    Erratum to: A novel function for p21 Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFbeta-mediated breast cancer cell migration and invasion.
    Breast Cancer Res. 2017;19:40.
    PubMed     Text format    


  48. WU Z, Shen S, Zhang Z, Zhang W, et al
    Erratum to: Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-small ka, CyrillicB mediated matrix metalloproteinase-1 gene regulation.
    Breast Cancer Res. 2017;19:41.
    PubMed     Text format    


  49. NAGALINGAM A, Arbiser JL, Bonner MY, Saxena NK, et al
    Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis.
    Breast Cancer Res. 2017;19:39.
    PubMed     Text format    


  50. DAI M, Al-Odaini AA, Fils-Aime N, Villatoro MA, et al
    Erratum to: Cyclin D1 cooperates with p21 to regulate TGFbeta-mediated breast cancer cell migration and tumor local invasion.
    Breast Cancer Res. 2017;19:43.
    PubMed     Text format    


  51. HOLEN I, Whitworth J, Nutter F, Evans A, et al
    Erratum to: Loss of plakoglobin promotes cell-cell contact, increased invasion and breast cancer cell dissemination in vivo.
    Breast Cancer Res. 2017;19:37.
    PubMed     Text format    


  52. PADAMSEE TJ, Wills CE, Yee LD, Paskett ED, et al
    Decision making for breast cancer prevention among women at elevated risk.
    Breast Cancer Res. 2017;19:34.
    PubMed     Text format     Abstract available


  53. FLAHERTY RL, Owen M, Fagan-Murphy A, Intabli H, et al
    Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer.
    Breast Cancer Res. 2017;19:35.
    PubMed     Text format     Abstract available


  54. PAQUET ER, Lesurf R, Tofigh A, Dumeaux V, et al
    Detecting gene signature activation in breast cancer in an absolute, single-patient manner.
    Breast Cancer Res. 2017;19:32.
    PubMed     Text format     Abstract available


  55. LI M, Tse LA, Chan WC, Kwok CH, et al
    Nighttime eating and breast cancer among Chinese women in Hong Kong.
    Breast Cancer Res. 2017;19:31.
    PubMed     Text format     Abstract available


  56. WALKER LC, Pearson JF, Wiggins GA, Giles GG, et al
    Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.
    Breast Cancer Res. 2017;19:30.
    PubMed     Text format     Abstract available


  57. ERIKSSON M, Czene K, Pawitan Y, Leifland K, et al
    A clinical model for identifying the short-term risk of breast cancer.
    Breast Cancer Res. 2017;19:29.
    PubMed     Text format     Abstract available


  58. XIONG J, Li J, Yang Q, Wang J, et al
    Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
    Breast Cancer Res. 2017;19:27.
    PubMed     Text format     Abstract available


  59. LEMLER DJ, Lynch ML, Tesfay L, Deng Z, et al
    DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms.
    Breast Cancer Res. 2017;19:25.
    PubMed     Text format     Abstract available


  60. BUEHRING GC
    Response to "Lack of association between bovine leukemia virus and breast cancer in Chinese patients".
    Breast Cancer Res. 2017;19:24.
    PubMed     Text format    


  61. SHACKSHAFT L, Van Hemelrijck M, Garmo H, Malmstrom H, et al
    Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort.
    Breast Cancer Res. 2017;19:22.
    PubMed     Text format     Abstract available


  62. BECA F, Kensler K, Glass B, Schnitt SJ, et al
    EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.
    Breast Cancer Res. 2017;19:21.
    PubMed     Text format     Abstract available


    February 2017
  63. BAILUR JK, Pawelec G, Hatse S, Brouwers B, et al
    Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty.
    Breast Cancer Res. 2017;19:20.
    PubMed     Text format     Abstract available


  64. MCCULLOUGH LE, Chen J, Cho YH, Khankari NK, et al
    Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes.
    Breast Cancer Res. 2017;19:19.
    PubMed     Text format     Abstract available


  65. MUSOLINO A, Campone M, Neven P, Denduluri N, et al
    Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
    Breast Cancer Res. 2017;19:18.
    PubMed     Text format     Abstract available


  66. HU Z, Mao JH, Curtis C, Huang G, et al
    Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
    Breast Cancer Res. 2017;19:17.
    PubMed     Text format    


  67. BIANCHINI G, Kiermaier A, Bianchi GV, Im YH, et al
    Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Breast Cancer Res. 2017;19:16.
    PubMed     Text format     Abstract available


  68. ZHANG X, Ren D, Guo L, Wang L, et al
    Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.
    Breast Cancer Res. 2017;19:15.
    PubMed     Text format     Abstract available


    January 2017
  69. BLACK KZ, Nichols HB, Eng E, Rowley DL, et al
    Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study.
    Breast Cancer Res. 2017;19:11.
    PubMed     Text format     Abstract available


  70. ELLINGJORD-DALE M, Vos L, Tretli S, Hofvind S, et al
    Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Breast Cancer Res. 2017;19:10.
    PubMed     Text format     Abstract available


  71. MULLOOLY M, Yang HP, Falk RT, Nyante SJ, et al
    Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.
    Breast Cancer Res. 2017;19:8.
    PubMed     Text format     Abstract available


  72. MA H, Ursin G, Xu X, Lee E, et al
    Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.
    Breast Cancer Res. 2017;19:6.
    PubMed     Text format     Abstract available


  73. LIU CY, Tseng LM, Su JC, Chang KC, et al
    Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Breast Cancer Res. 2017;19:5.
    PubMed     Text format    


  74. ETHIER JL, Desautels D, Templeton A, Shah PS, et al
    Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res. 2017;19:2.
    PubMed     Text format     Abstract available


  75. GROHEUX D, Martineau A, Teixeira L, Espie M, et al
    18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.
    Breast Cancer Res. 2017;19:3.
    PubMed     Text format     Abstract available


  76. MALKOV S, Shepherd JA, Scott CG, Tamimi RM, et al
    Erratum to: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.
    Breast Cancer Res. 2017;19:1.
    PubMed     Text format    


    December 2016
  77. HORN-ROSS PL, Canchola AJ, Bernstein L, Neuhausen SL, et al
    Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort.
    Breast Cancer Res. 2016;18:132.
    PubMed     Text format     Abstract available


  78. UEHIRO N, Sato F, Pu F, Tanaka S, et al
    Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Breast Cancer Res. 2016;18:129.
    PubMed     Text format     Abstract available


  79. WEN W, Shu XO, Guo X, Cai Q, et al
    Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry.
    Breast Cancer Res. 2016;18:124.
    PubMed     Text format     Abstract available


  80. YOUNG AI, Law AM, Castillo L, Chong S, et al
    MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Breast Cancer Res. 2016;18:125.
    PubMed     Text format     Abstract available


  81. MALKOV S, Shepherd JA, Scott CG, Tamimi RM, et al
    Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.
    Breast Cancer Res. 2016;18:122.
    PubMed     Text format     Abstract available


  82. CARDWELL CR, Pottegard A, Vaes E, Garmo H, et al
    Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.
    Breast Cancer Res. 2016;18:119.
    PubMed     Text format     Abstract available


  83. HUANG YS, Chen JL, Huang CS, Kuo SH, et al
    High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study.
    Breast Cancer Res. 2016;18:120.
    PubMed     Text format     Abstract available


  84. SELLI C, Dixon JM, Sims AH
    Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.
    Breast Cancer Res. 2016;18:118.
    PubMed     Text format     Abstract available


    November 2016
  85. LI LL, Xue AM, Li BX, Shen YW, et al
    Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
    Breast Cancer Res. 2016;18:114.
    PubMed     Text format    


  86. CATUCCI I, Radice P, Milne RL, Couch FJ, et al
    The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk.
    Breast Cancer Res. 2016;18:111.
    PubMed     Text format    


  87. LINDSTROM S, Ablorh A, Chapman B, Gusev A, et al
    Deep targeted sequencing of 12 breast cancer susceptibility regions in 4611 women across four different ethnicities.
    Breast Cancer Res. 2016;18:109.
    PubMed     Text format     Abstract available


    October 2016
  88. ABUBAKAR M, Orr N, Daley F, Coulson P, et al
    Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
    Breast Cancer Res. 2016;18:104.
    PubMed     Text format     Abstract available


  89. SACKEY H, Hui M, Czene K, Verkooijen H, et al
    The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden.
    Breast Cancer Res. 2016;18:105.
    PubMed     Text format     Abstract available


  90. ROMANUS S, Neven P, Soubry A
    Extending the Developmental Origins of Health and Disease theory: does paternal diet contribute to breast cancer risk in daughters?
    Breast Cancer Res. 2016;18:103.
    PubMed     Text format     Abstract available


  91. ZHANG R, Jiang J, Sun W, Zhang J, et al
    Lack of association between bovine leukemia virus and breast cancer in Chinese patients.
    Breast Cancer Res. 2016;18:101.
    PubMed     Text format    


  92. STRAND F, Humphreys K, Cheddad A, Tornberg S, et al
    Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study.
    Breast Cancer Res. 2016;18:100.
    PubMed     Text format     Abstract available


  93. SKOL AD, Sasaki MM, Onel K
    The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance.
    Breast Cancer Res. 2016;18:99.
    PubMed     Text format     Abstract available


  94. MURANEN TA, Blomqvist C, Dork T, Jakubowska A, et al
    Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Breast Cancer Res. 2016;18:98.
    PubMed     Text format     Abstract available


    April 2016
  95. LUNDBERG FE, Johansson AL, Rodriguez-Wallberg K, Brand JS, et al
    Association of infertility and fertility treatment with mammographic density in a large screening-based cohort of women: a cross-sectional study.
    Breast Cancer Res. 2016;18:36.
    PubMed     Text format     Abstract available


  96. LEROY C, Ramos P, Cornille K, Bonenfant D, et al
    Activation of IGF1R/p110beta/AKT/mTOR confers resistance to alpha-specific PI3K inhibition.
    Breast Cancer Res. 2016;18:41.
    PubMed     Text format     Abstract available


  97. LOPEZ-KNOWLES E, Gao Q, Cheang MC, Morden J, et al
    Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
    Breast Cancer Res. 2016;18:39.
    PubMed     Text format     Abstract available


    March 2016
  98. ESBONA K, Inman D, Saha S, Jeffery J, et al
    COX-2 modulates mammary tumor progression in response to collagen density.
    Breast Cancer Res. 2016;18:35.
    PubMed     Text format     Abstract available


  99. WEIGAND A, Boos AM, Tasbihi K, Beier JP, et al
    Selective isolation and characterization of primary cells from normal breast and tumors reveal plasticity of adipose derived stem cells.
    Breast Cancer Res. 2016;18:32.
    PubMed     Text format     Abstract available


  100. TAN WJ, Cima I, Choudhury Y, Wei X, et al
    A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions.
    Breast Cancer Res. 2016;18:31.
    PubMed     Text format     Abstract available


  101. SOKOL ES, Miller DH, Breggia A, Spencer KC, et al
    Growth of human breast tissues from patient cells in 3D hydrogel scaffolds.
    Breast Cancer Res. 2016;18:19.
    PubMed     Text format     Abstract available


    February 2016
  102. HOLM K, Staaf J, Lauss M, Aine M, et al
    An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
    Breast Cancer Res. 2016;18:27.
    PubMed     Text format     Abstract available


  103. HORNE HN, Sherman ME, Pfeiffer RM, Figueroa JD, et al
    Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease.
    Breast Cancer Res. 2016;18:24.
    PubMed     Text format     Abstract available


  104. GRUEL N, Fuhrmann L, Lodillinsky C, Benhamo V, et al
    LIN7A is a major determinant of cell-polarity defects in breast carcinomas.
    Breast Cancer Res. 2016;18:23.
    PubMed     Text format     Abstract available


  105. PETRIDIS C, Brook MN, Shah V, Kohut K, et al
    Genetic predisposition to ductal carcinoma in situ of the breast.
    Breast Cancer Res. 2016;18:22.
    PubMed     Text format     Abstract available


  106. KASIMIR-BAUER S, Bittner AK, Konig L, Reiter K, et al
    Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Breast Cancer Res. 2016;18:20.
    PubMed     Text format     Abstract available


  107. JOHNSTON RL, Wockner L, McCart Reed AE, Wiegmans A, et al
    High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations.
    Breast Cancer Res. 2016;18:18.
    PubMed     Text format     Abstract available


  108. FINN RS, Aleshin A, Slamon DJ
    Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
    Breast Cancer Res. 2016;18:17.
    PubMed     Text format     Abstract available


    January 2016
  109. WARD AK, Mellor P, Smith SE, Kendall S, et al
    Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Breast Cancer Res. 2016;18:12.
    PubMed     Text format     Abstract available


  110. GRAVES ML, Cipollone JA, Austin P, Bell EM, et al
    The cell surface mucin podocalyxin regulates collective breast tumor budding.
    Breast Cancer Res. 2016;18:11.
    PubMed     Text format     Abstract available


  111. WANG M, Klevebring D, Lindberg J, Czene K, et al
    Determining breast cancer histological grade from RNA-sequencing data.
    Breast Cancer Res. 2016;18:48.
    PubMed     Text format     Abstract available


  112. VAN LUIJT PA, Heijnsdijk EA, Fracheboud J, Overbeek LI, et al
    The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
    Breast Cancer Res. 2016;18:47.
    PubMed     Text format     Abstract available


  113. HINZEY A, Gaudier-Diaz MM, Lustberg MB, DeVries AC, et al
    Breast cancer and social environment: getting by with a little help from our friends.
    Breast Cancer Res. 2016;18:54.
    PubMed     Text format     Abstract available


  114. HABEL LA, Lipson JA, Achacoso N, Rothstein JH, et al
    Case-control study of mammographic density and breast cancer risk using processed digital mammograms.
    Breast Cancer Res. 2016;18:53.
    PubMed     Text format     Abstract available


  115. MORRISSEY B, Blyth K, Carter P, Chelala C, et al
    SEARCHBreast: a new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers.
    Breast Cancer Res. 2016;18:59.
    PubMed     Text format    


  116. SIMIGDALA N, Gao Q, Pancholi S, Roberg-Larsen H, et al
    Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2016;18:58.
    PubMed     Text format     Abstract available


  117. WEN WX, Soo JS, Kwan PY, Hong E, et al
    Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
    Breast Cancer Res. 2016;18:56.
    PubMed     Text format     Abstract available


  118. MA H, Xu X, Clague J, Lu Y, et al
    Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study.
    Breast Cancer Res. 2016;18:62.
    PubMed     Text format     Abstract available


  119. KRISHNAN K, Baglietto L, Apicella C, Stone J, et al
    Mammographic density and risk of breast cancer by mode of detection and tumor size: a case-control study.
    Breast Cancer Res. 2016;18:63.
    PubMed     Text format     Abstract available


  120. ALLOTT EH, Geradts J, Sun X, Cohen SM, et al
    Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Breast Cancer Res. 2016;18:68.
    PubMed     Text format     Abstract available


  121. FINN RS, Crown JP, Ettl J, Schmidt M, et al
    Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
    Breast Cancer Res. 2016;18:67.
    PubMed     Text format     Abstract available


  122. WILSON LE, D'Aloisio AA, Sandler DP, Taylor JA, et al
    Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women.
    Breast Cancer Res. 2016;18:61.
    PubMed     Text format     Abstract available


  123. MIYOSHI Y, Shien T, Ogiya A, Ishida N, et al
    Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Breast Cancer Res. 2016;18:73.
    PubMed     Text format     Abstract available


  124. HU Z, Mao JH, Curtis C, Huang G, et al
    Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
    Breast Cancer Res. 2016;18:70.
    PubMed     Text format     Abstract available


  125. LANGBALLE R, Mellemkjaer L, Malone KE, Lynch CF, et al
    Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
    Breast Cancer Res. 2016;18:65.
    PubMed     Text format     Abstract available


  126. SCHOEMAKER MJ, Jones ME, Wright LB, Griffin J, et al
    Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom.
    Breast Cancer Res. 2016;18:72.
    PubMed     Text format     Abstract available


  127. ZENG C, Guo X, Long J, Kuchenbaecker KB, et al
    Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
    Breast Cancer Res. 2016;18:64.
    PubMed     Text format     Abstract available


  128. LOANE J
    Comment on: Tan WJ, Cima I, Choudhury Y, Wei X, Lim JCT, Thicke AA, Tan MH, Tan PH. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Research 2016;18:31.
    Breast Cancer Res. 2016;18:77.
    PubMed     Text format    


  129. FONTELLES CC, Guido LN, Rosim MP, Andrade Fde O, et al
    Paternal programming of breast cancer risk in daughters in a rat model: opposing effects of animal- and plant-based high-fat diets.
    Breast Cancer Res. 2016;18:71.
    PubMed     Text format     Abstract available


  130. NOGALES-CADENAS R, Cai Y, Lin JR, Zhang Q, et al
    MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice.
    Breast Cancer Res. 2016;18:75.
    PubMed     Text format     Abstract available


  131. WU S, Berg WA, Zuley ML, Kurland BF, et al
    Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.
    Breast Cancer Res. 2016;18:76.
    PubMed     Text format     Abstract available


  132. MANI NL, Schalper KA, Hatzis C, Saglam O, et al
    Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.
    Breast Cancer Res. 2016;18:78.
    PubMed     Text format     Abstract available


  133. BOURGEOIS-DAIGNEAULT MC, St-Germain LE, Roy DG, Pelin A, et al
    Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
    Breast Cancer Res. 2016;18:83.
    PubMed     Text format     Abstract available


  134. LOO CE, Rigter LS, Pengel KE, Wesseling J, et al
    Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Breast Cancer Res. 2016;18:82.
    PubMed     Text format     Abstract available


  135. SETHURAMAN A, Brown M, Seagroves TN, Wu ZH, et al
    SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway.
    Breast Cancer Res. 2016;18:81.
    PubMed     Text format     Abstract available


  136. CHOLLET-HINTON L, Anders CK, Tse CK, Bell MB, et al
    Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study.
    Breast Cancer Res. 2016;18:79.
    PubMed     Text format     Abstract available


  137. PALMER JR, Gerlovin H, Bethea TN, Bertrand KA, et al
    Predicted 25-hydroxyvitamin D in relation to incidence of breast cancer in a large cohort of African American women.
    Breast Cancer Res. 2016;18:86.
    PubMed     Text format     Abstract available


  138. BLAKEMAN V, Williams JL, Meng QJ, Streuli CH, et al
    Circadian clocks and breast cancer.
    Breast Cancer Res. 2016;18:89.
    PubMed     Text format     Abstract available


  139. HANNAFON BN, Trigoso YD, Calloway CL, Zhao YD, et al
    Plasma exosome microRNAs are indicative of breast cancer.
    Breast Cancer Res. 2016;18:90.
    PubMed     Text format     Abstract available


  140. ILMER M, Mazurek N, Gilcrease MZ, Byrd JC, et al
    Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
    Breast Cancer Res. 2016;18:97.
    PubMed     Text format     Abstract available


  141. BUSANA MC, Eng A, Denholm R, Dowsett M, et al
    Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study.
    Breast Cancer Res. 2016;18:96.
    PubMed     Text format     Abstract available


  142. BYERLY J, Halstead-Nussloch G, Ito K, Katsyv I, et al
    PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Breast Cancer Res. 2016;18:95.
    PubMed     Text format     Abstract available


  143. RICE MS, Bertrand KA, VanderWeele TJ, Rosner BA, et al
    Mammographic density and breast cancer risk: a mediation analysis.
    Breast Cancer Res. 2016;18:94.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: